Abstract：
OBJECTIVE: The incidence and severity of diabetes is particularly high in the French overseas territories (FOT). The RECIF study evaluated real life management of diabetic macular oedema (DME) treated by aflibercept in FOT.
METHODS: A prospective, noncomparative, multicentric, non-interventional, study that evaluated functional and anatomical results of patients treated by aflibercept. Twelve retina specialists working in French Polynesia, La Reunion, Guadeloupe and Martinique participated in the study.
RESULTS: 67 eyes of 57 patients were followed for 12 months. Average VA gain was 7.8 ETDRS letters. 29.9% of eyes gained at least 15 letters, 6% lost 15 letters or more. 67.2% of eyes achieved visual acuity of 70 letters or better. Average central retinal thickness decrease was 115.3 µm. The mean number of injections during the 1st year of treatment was 4.9. 69% of eyes had a loading dose of at least three-monthly injections. 3 eyes were switched to steroid injections during the follow-up for lack of efficacy.
CONCLUSIONS: This study confirmed the efficacy of intravitreal treatment of DME by aflibercept, in the French overseas territories. This evaluation of real-life management of DME underlines the importance of improvement of patient education and collaboration with referring physicians.
METHODS: A prospective, noncomparative, multicentric, non-interventional, study that evaluated functional and anatomical results of patients treated by aflibercept. Twelve retina specialists working in French Polynesia, La Reunion, Guadeloupe and Martinique participated in the study.
RESULTS: 67 eyes of 57 patients were followed for 12 months. Average VA gain was 7.8 ETDRS letters. 29.9% of eyes gained at least 15 letters, 6% lost 15 letters or more. 67.2% of eyes achieved visual acuity of 70 letters or better. Average central retinal thickness decrease was 115.3 µm. The mean number of injections during the 1st year of treatment was 4.9. 69% of eyes had a loading dose of at least three-monthly injections. 3 eyes were switched to steroid injections during the follow-up for lack of efficacy.
CONCLUSIONS: This study confirmed the efficacy of intravitreal treatment of DME by aflibercept, in the French overseas territories. This evaluation of real-life management of DME underlines the importance of improvement of patient education and collaboration with referring physicians.
摘要：
目的：在法国海外领土（FOT），糖尿病的发病率和严重程度特别高。RECIF研究评估了FOT中阿柏西普治疗的糖尿病性黄斑水肿（DME）的现实生活管理。
方法：前瞻性，非比较性，多中心,非干预性，评估阿柏西普治疗患者的功能和解剖学结果的研究。十二位在法属波利尼西亚工作的视网膜专家，留尼汪岛,瓜德罗普岛和马提尼克岛参加了这项研究。
结果：57例患者67只眼随访12个月。平均VA增益为7.8个ETDRS字母。29.9％的眼睛至少获得了15个字母，6%的人丢失了15个字母或更多。67.2%的眼睛视力达到70字母或更好。平均中央视网膜厚度减少为115.3µm。治疗第一年的平均注射次数为4.9次。69%的眼睛有至少三个月注射的负荷剂量。3只眼在随访期间因缺乏疗效而改用类固醇注射。
结论：本研究证实了阿柏西普玻璃体内治疗DME的疗效，在法国海外领土。对DME的现实生活管理的评估强调了改善患者教育和与转诊医师合作的重要性。
方法：前瞻性，非比较性，多中心,非干预性，评估阿柏西普治疗患者的功能和解剖学结果的研究。十二位在法属波利尼西亚工作的视网膜专家，留尼汪岛,瓜德罗普岛和马提尼克岛参加了这项研究。
结果：57例患者67只眼随访12个月。平均VA增益为7.8个ETDRS字母。29.9％的眼睛至少获得了15个字母，6%的人丢失了15个字母或更多。67.2%的眼睛视力达到70字母或更好。平均中央视网膜厚度减少为115.3µm。治疗第一年的平均注射次数为4.9次。69%的眼睛有至少三个月注射的负荷剂量。3只眼在随访期间因缺乏疗效而改用类固醇注射。
结论：本研究证实了阿柏西普玻璃体内治疗DME的疗效，在法国海外领土。对DME的现实生活管理的评估强调了改善患者教育和与转诊医师合作的重要性。
